Clinical Trial

Asian Diabetes Outcomes Prevention Trial

Study acronym: ADOPT
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2021 (before its estimated June 30, 2022 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to identify patients with DM at high risk of CVD using elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (\>125pg/mL), and (2) intensify therapy using renin-angiotensin system (RAS) antagonists, beta-blockers and sodium glucose co-transporter-2 inhibitors (SGLT2i) for primary prevention of cardiovascular events in this high-risk DM population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-02-24.
Trial Details
NCT Number NCT04286399
Lead Sponsor National Heart Centre Singapore
Collaborators: Singapore General Hospital, Mackay Memorial Hospital, National Taiwan University Hospital, Peking University People's Hospital, Medanta, The Medicity, India, Public Health Foundation of India, Putrajaya Hospital, Malaysia, Universiti Teknologi Mara
Conditions Diabetes Mellitus, Cardiovascular Diseases
Enrollment 2,400 participants
Start Date 2019-07-01
Primary Completion 2022-06-30 (estimated)
Study Completion 2034-06-30 (estimated)
Updated on ClinicalTrials.gov 2021-04-30